Electra Therapeutics, Inc. (ETRA) stock
ETRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$8.35+0.04 (+0.48%)
Close on Nov 17, 2026Market cap $524.94MP/E –Yield –
Electra Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $17.27M | – |
| Q3 FY2025 | Sep 30, 2025 | $14.90M | – |
See a number that looks wrong?